#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Polymyositis Sjogren's syndrome Systemic candida Congenital generalised lipodystrophy Myelodysplastic syndrome with excess blasts Acute promyelocytic leukaemia Central nervous system lymphoma Short stature Sarcoma Acute myeloid leukaemia recurrent Extra-osseous Ewing's sarcoma Round cell liposarcoma Myxofibrosarcoma Keratosis follicular Oesophageal squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Breast angiosarcoma – Basic Information Leiomyosarcoma – Basic Information Rhabdomyosarcoma – Treatment Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics Familial amyotrophic lateral sclerosis – Treatment Waldenstrom’s macroglobulinaemia – Treatment Castleman’s disease – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Trials in Disease Gaucher’s disease type III Haemophilia A with anti factor VIII – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dnth103 Dicloxacillin APAZUNERSEN Ixazomib Rbl007.2 Lolium Perenne NALOXEGOL ALENDRONATE SODIUM TRIHYDRATE Vamorolone Levetiracetam SIGVOTATUG VEDOTIN Magnesium Stearate Gad20-209-Fsp-A1 Inaxaplin Silibinin Nimodipine Irinotecan Hydrochloride OBI-821 GSKVX000000070965 Ropivacaine More therapies…

    Learn about Your Condition

    Milk allergy Cerebral amyloid angiopathy Hypertonic bladder Inflammatory bowel disease Bronchopulmonary aspergillosis Nephropathy Hairy cell leukaemia recurrent Genital herpes Myasthenia gravis Hepatic angiosarcoma Follicular lymphoma stage IV Haemofiltration Neuroendocrine carcinoma Chronic sinusitis Pruritus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Haga Hospital

Haga Hospital

Els Borst-Eilersplein 275, Hague, 2545 AA, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Carboplatin
    The Netherlands

  • Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Palbociclib
    Austria Belgium Germany Hungary Ireland Italy +5

  • Study on the Effect of Clopidogrel and Acetylsalicylic Acid on Reducing Heart and Blood Vessel Events in Patients with Peripheral Arterial Disease

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Clopidogrel
    • Lactose Monohydrate
    • Acetylsalicylic Acid
    The Netherlands

  • Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Embolism venous
    Investigated Drugs:
    • Abelacimab
    • Apixaban
    Austria Czechia France Germany Hungary Ireland +6

  • Study on the Effect of Adding Leuprorelin Acetate to Radiotherapy for Patients with Oligo-recurrent Prostate Cancer with Up to 4 Metastases

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    The Netherlands

  • Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Embolism venous
    • Gastrointestinal cancer metastatic
    Investigated Drugs:
    • Abelacimab
    • Dalteparin Sodium
    Austria Czechia France Germany Hungary Ireland +6

  • Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Bortezomib
    • Daratumumab
    Austria Belgium Czechia Denmark Finland France +10

  • Comparison of Atropine 0.

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myopia
    Investigated Drugs:
    • Atropine Sulfate
    The Netherlands

  • Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Capivasertib
    • Docetaxel
    Belgium Czechia France Greece Hungary The Netherlands +2

  • Study on the Effects of Belimumab and Rituximab for Patients with Severe Systemic Lupus Erythematosus

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Glomerulonephritis
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Belimumab
    • Rituximab
    The Netherlands
Previous Page
1 … 6 7 8 9 10 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!